Partnership to Provide Bioanalytical and DMPK Services

Integrated drug discovery, development and analytical services company Concept Life Sciences and Alderley Analytical, a GLP/GCP compliant, bioanalytical contract research organisation have signed a partnership agreement to provide high-value bioanalytical and DMPK study services.

Under the terms of the agreement, Concept will gain access to Alderley Analytical’s significant expertise in bioanalysis and Alderley Analytical will benefit from Concept’s experience in synthetic, organic and medicinal chemistry, biology, toxicology and analytical services. The combined offering will give clients of both companies access to assay development services for quantification of new molecules in a biological matrix.

Michael Fort, Executive Chairman, Concept Life Sciences, commented: “The team at Alderley Analytical has built an impressive reputation for delivery of the highest quality GLP/GCP bioanalytical services. Combining this offering with our Group’s expertise, including the recent additions of translational biology and large molecule research, brings benefits to the widest group of life sciences clients.”

Liz Thomas, CEO, Alderley Analytical, said: “We are delighted to be partnering with Concept Life Sciences group at this stage in our company’s development. Concept’s size, business development network and complementary scientific capability will make the enhanced service offering highly attractive and beneficial to a wide group of national and international clients.”